New treatment option for breast cancer

A new drug for women whose breast cancer fails to respond to conventional chemotherapy has been listed on Australia’s Pharmaceutical Benefits Scheme.

Abraxane, approved in more than 35 countries, has been shown to slow the progression of the cancer and extend overall survival with reduced risk of side-effects.
“Many women have problems tolerating some existing chemotherapies, due to the corticosteroids required to minimise severe hypersensitivity reactions,” says Associate Professor Fran Boyle from Sydney’s Mater Hospital.
“So it is a pleasing addition to the oncologists’ drug armamentarium.”
Dr Boyle said women who benefited from their existing chemotherapy should not change but should discuss their options with their doctor